Hirotaka Iwase

7.9k total citations
210 papers, 6.2k citations indexed

About

Hirotaka Iwase is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, Hirotaka Iwase has authored 210 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 111 papers in Oncology, 87 papers in Cancer Research and 76 papers in Genetics. Recurrent topics in Hirotaka Iwase's work include Estrogen and related hormone effects (57 papers), HER2/EGFR in Cancer Research (55 papers) and Breast Cancer Treatment Studies (51 papers). Hirotaka Iwase is often cited by papers focused on Estrogen and related hormone effects (57 papers), HER2/EGFR in Cancer Research (55 papers) and Breast Cancer Treatment Studies (51 papers). Hirotaka Iwase collaborates with scholars based in Japan, United States and China. Hirotaka Iwase's co-authors include Yutaka Yamamoto, Hiroko Yamashita, Tatsuya Toyama, Shunzo Kobayashi, Zhenhuan Zhang, Yoko Omoto, Hiroshi Sugiura, Yukio Ando, Mutsuko Yamamoto‐Ibusuki and Yoshitaka Fujii and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Hirotaka Iwase

207 papers receiving 6.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hirotaka Iwase Japan 47 3.0k 2.9k 2.2k 1.5k 840 210 6.2k
C. Kent Osborne United States 33 2.9k 1.0× 2.2k 0.7× 2.1k 0.9× 1.8k 1.2× 743 0.9× 82 5.6k
M. Kaufmann Germany 41 3.6k 1.2× 1.6k 0.6× 2.5k 1.1× 1.2k 0.8× 828 1.0× 242 6.5k
Pär‐Ola Bendahl Sweden 44 3.3k 1.1× 2.7k 0.9× 3.0k 1.3× 928 0.6× 1.4k 1.6× 181 6.7k
Helga B. Salvesen Norway 49 1.6k 0.5× 3.0k 1.0× 1.5k 0.7× 762 0.5× 826 1.0× 153 6.9k
Rinat Yerushalmi Israel 27 4.4k 1.5× 2.2k 0.8× 2.3k 1.0× 1.2k 0.8× 1.8k 2.1× 119 6.7k
Dilip D. Giri United States 37 2.9k 1.0× 3.0k 1.0× 2.4k 1.1× 728 0.5× 712 0.8× 94 7.0k
D. Craig Allred United States 32 4.5k 1.5× 2.8k 1.0× 3.4k 1.5× 2.4k 1.6× 931 1.1× 54 7.5k
Thomas Hatschek Sweden 29 2.4k 0.8× 1.1k 0.4× 1.9k 0.9× 754 0.5× 956 1.1× 100 4.5k
Mark L. Graham United States 26 2.2k 0.7× 1.3k 0.4× 1.7k 0.8× 1.1k 0.7× 574 0.7× 53 4.5k
Paul D. Smith United Kingdom 45 2.4k 0.8× 5.1k 1.7× 1.4k 0.6× 771 0.5× 1.4k 1.7× 120 7.5k

Countries citing papers authored by Hirotaka Iwase

Since Specialization
Citations

This map shows the geographic impact of Hirotaka Iwase's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hirotaka Iwase with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hirotaka Iwase more than expected).

Fields of papers citing papers by Hirotaka Iwase

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hirotaka Iwase. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hirotaka Iwase. The network helps show where Hirotaka Iwase may publish in the future.

Co-authorship network of co-authors of Hirotaka Iwase

This figure shows the co-authorship network connecting the top 25 collaborators of Hirotaka Iwase. A scholar is included among the top collaborators of Hirotaka Iwase based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hirotaka Iwase. Hirotaka Iwase is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Pegram, Mark D., Igor Bondarenko, Hirotaka Iwase, et al.. (2018). PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study. British Journal of Cancer. 120(2). 172–182. 50 indexed citations
3.
Fujiwara, Saori, Mutsuko Yamamoto‐Ibusuki, Yutaka Yamamoto, et al.. (2014). The localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2- breast cancer. Oncotarget. 5(11). 3919–3930. 19 indexed citations
4.
Yamamoto‐Ibusuki, Mutsuko, Yutaka Yamamoto, Peifen Fu, et al.. (2013). Divisional role of quantitative HER2 testing in breast cancer. Breast Cancer. 22(2). 161–171. 3 indexed citations
5.
Yamamoto, Yutaka & Hirotaka Iwase. (2010). Clinicopathological features and treatment strategy for triple-negative breast cancer. International Journal of Clinical Oncology. 15(4). 341–351. 44 indexed citations
6.
Zhang, Zhenhuan, Hiroko Yamashita, Tatsuya Toyama, et al.. (2009). Nuclear corepressor 1 expression predicts response to first-line endocrine therapy for breast cancer patients on relapse.. PubMed. 122(15). 1764–8. 10 indexed citations
7.
Yamamoto, Yutaka, et al.. (2009). Clinical significance of basal-like subtype in triple-negative breast cancer. Breast Cancer. 16(4). 260–267. 55 indexed citations
8.
Nakano, Masahiro, Yutaka Yamamoto, Teru Kawasoe, et al.. (2009). [A case of spindle cell carcinoma of the breast including metaplastic lesion with poor prognosis].. PubMed. 36(6). 1017–9. 1 indexed citations
9.
Akiyama, Futoshi & Hirotaka Iwase. (2009). Triple negative breast cancer: clinicopathological characteristics and treatment strategies. Breast Cancer. 16(4). 252–253. 12 indexed citations
10.
11.
Nishiyama, Yasuyuki, et al.. (2008). INFLAMMATORY BREAST RECURRENCE AFTER PREOPERATIVE CHEMOTHERAPY FOLLOWED BY PATHOLOGICAL COMPLETE RESPONSE. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 69(11). 2809–2812.
12.
Zhang, Zhenhuan, Hiroko Yamashita, Tatsuya Toyama, et al.. (2006). Reduced Expression of theBreast Cancer Metastasis Suppressor 1mRNA Is Correlated with Poor Progress in Breast Cancer. Clinical Cancer Research. 12(21). 6410–6414. 54 indexed citations
13.
Zhang, Zhenhuan, Hiroko Yamashita, Tatsuya Toyama, et al.. (2005). NCOR1 mRNA is an independent prognostic factor for breast cancer. Cancer Letters. 237(1). 123–129. 30 indexed citations
14.
Zhang, Zhenhuan, Hiroko Yamashita, Tatsuya Toyama, et al.. (2005). Quantitation of HDAC1 mRNA Expression in Invasive Carcinoma of the Breast*. Breast Cancer Research and Treatment. 94(1). 11–16. 247 indexed citations
15.
Yamashita, Hiroko, Mariko Nishio, Shunzo Kobayashi, et al.. (2005). Phosphorylation of estrogen receptor α serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer. Breast Cancer Research. 7(5). R753–64. 90 indexed citations
16.
Toyama, Tatsuya, Hirotaka Iwase, Hiroko Yamashita, et al.. (2003). p33ING1b stimulates the transcriptional activity of the estrogen receptor α via its activation function (AF) 2 domain. The Journal of Steroid Biochemistry and Molecular Biology. 87(1). 57–63. 15 indexed citations
17.
Yamashita, Hiroko, Mariko Nishio, Tatsuya Toyama, et al.. (2003). Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Research. 6(1). R24–30. 125 indexed citations
18.
Iwase, Hirotaka, Y. Itoh, Hidetoshi Yamashita, et al.. (1997). Simultaneous quantitative analyses of c-erbB-2 protein, epidermal growth factor receptor, cathepsin D, and hormone receptors in breast cancer.. PubMed. 21(1). 29–35. 11 indexed citations
19.
Iwase, Hirotaka, Shunzo Kobayashi, Hiroaki Iwata, et al.. (1996). [Molecular analysis of the estrogen receptor (ER) gene in association with ER negativity in breast cancer].. PubMed. 23 Suppl 1. 61–5. 2 indexed citations
20.
Iwase, Hirotaka, et al.. (1990). A case of pancreatic cancer including osteoclast-like gaiant cells.. The Japanese Journal of Gastroenterological Surgery. 23(5). 1186–1190. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by C. Kent Osborne Breakdown of academic impact, for papers by M. Kaufmann Breakdown of academic impact, for papers by Pär‐Ola Bendahl Breakdown of academic impact, for papers by Helga B. Salvesen Breakdown of academic impact, for papers by Rinat Yerushalmi Breakdown of academic impact, for papers by Dilip D. Giri Breakdown of academic impact, for papers by D. Craig Allred Breakdown of academic impact, for papers by Thomas Hatschek Breakdown of academic impact, for papers by Mark L. Graham Breakdown of academic impact, for papers by Paul D. Smith
Rankless by CCL
2026